trending Market Intelligence /marketintelligence/en/news-insights/trending/-j01Pz-EKEkK_0TB6jah4g2 content esgSubNav
In This List

AbCellera, Pfizer partner to conduct antibody research

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


AbCellera, Pfizer partner to conduct antibody research

AbCellera Biologics Inc. and Pfizer Inc. entered a collaboration agreement for the discovery of new therapeutic antibodies.

AbCellera will use its proprietary monoclonal antibody screening platform to find function-modulating antibodies against undisclosed membrane protein targets.

Under the terms of the agreement, AbCellera will receive an upfront payment and research support and will be eligible to receive up to about $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer's development and commercialization of antibodies that may be generated under the collaboration.

Further terms of the agreement are not disclosed.